» Articles » PMID: 37536953

Induced Fit Describes Ligand Binding to Membrane-Associated Cytochrome P450 3A4

Overview
Journal Mol Pharmacol
Date 2023 Aug 3
PMID 37536953
Authors
Affiliations
Soon will be listed here.
Abstract

Cytochrome P450 3A4 (CYP3A4) is the dominant P450 involved in human xenobiotic metabolism. Competition for CYP3A4 therefore underlies several adverse drug-drug interactions. Despite its clinical significance, the mechanisms CYP3A4 uses to bind diverse ligands remain poorly understood. Highly monodisperse CYP3A4 embedded in anionic lipoprotein nanodiscs containing an equal mixture of 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) were used to determine which of the limiting kinetic schemes that include protein conformational change, conformational selection (CS) or induced fit (IF), best described the binding of four known irreversible inhibitors. Azamulin, retapamulin, pleuromutilin, and mibrefadil binding to CYP3A4 nanodiscs conformed to a single-site binding model. Exponential fits of stopped-flow UV-visible absorption spectroscopy data supported multiple-step binding mechanisms. Trends in the rates of relaxation to equilibrium with increasing ligand concentrations were ambiguous as to whether IF or CS was involved; however, global fitting and consideration of the rate constants favored an IF mechanism. In the case of mibrefadil, a transient complex was observed in the stopped-flow UV-visible experiment, definitively assigning the presence of IF in ligand binding. While these studies only consider a small region of CYP3A4's vast ligand space, they provide kinetic evidence that CYP3A4 can use an IF mechanism. SIGNIFICANCE STATEMENT: CYP3A4 is capable of oxidizing numerous xenobiotics, including many drugs. Such promiscuity could not be achieved without conformational changes to accommodate diverse substrates. It is unknown whether conformational heterogeneity is present before (conformational selection) or after (induced fit) ligand binding. Stopped-flow measurements of suicide inhibitors binding to nanodisc-embedded CYP3A4 combined with sophisticated numerical analyses support that induced fit better describes ligand binding to this important enzyme.

Citing Articles

Kinetics of Intermediate Release Enhances P450 11B2-Catalyzed Aldosterone Synthesis.

Valentin-Goyco J, Im S, Auchus R Biochemistry. 2024; 63(8):1026-1037.

PMID: 38564530 PMC: 11259377. DOI: 10.1021/acs.biochem.3c00725.

References
1.
Hackett J . Membrane-embedded substrate recognition by cytochrome P450 3A4. J Biol Chem. 2018; 293(11):4037-4046. PMC: 5857991. DOI: 10.1074/jbc.RA117.000961. View

2.
Zanger U, Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41. DOI: 10.1016/j.pharmthera.2012.12.007. View

3.
Sevrioukova I, Poulos T . Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand. J Biol Chem. 2011; 287(5):3510-7. PMC: 3271004. DOI: 10.1074/jbc.M111.317081. View

4.
Welker H, Wiltshire H, Bullingham R . Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet. 1999; 35(6):405-23. DOI: 10.2165/00003088-199835060-00001. View

5.
VAN Holde K . A hypothesis concerning diffusion-limited protein-ligand interactions. Biophys Chem. 2002; 101-102:249-54. DOI: 10.1016/s0301-4622(02)00176-x. View